← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Pluri PLUR $12M	18	+18	–	$1.09M
27	27 Arbutus Biopharma ABUS $844M	11	+11	–	$6.09M
28	28 DELISTED bluebird bio BLUE	6	+6	–	$15.2M
29	29 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	6	+6	–	$167K
30	30 Eterna Therapeutics ERNA $2.45M	3	+3	–	$2.18M
31	NSTG 31 DELISTED NanoString Technologies, Inc. NSTG	3	+3	–	$4.47M
32	32 PTC Therapeutics PTCT $5.16B	3	+3	–	$3.47M
33	33 Abeona Therapeutics ABEO $261M	–	–	–	–
34	34 Adicet Bio ACET $47.2M	–	–	–	–
35	ACHL 35 DELISTED Achilles Therapeutics ACHL	–	–	–	–
36	36 DELISTED Arcellx ACLX	–	–	–	–
37	ADAP 37 DELISTED Adaptimmune Therapeutics ADAP	–	–	–	–
38	38 Adaptive Biotechnologies ADPT $4.04B	–	–	–	–
39	39 DELISTED Adverum Biotechnologies ADVM	–	–	–	–
40	AGTC 40 DELISTED Applied Genetic Technologies Corporation AGTC	–	–	–	–
41	AKUS 41 DELISTED Akouos Inc AKUS	–	–	–	–
42	42 Allogene Therapeutics ALLO $460M	–	–	–	–
43	43 ALPS Group Inc ALPS $56.6M	–	–	–	–
44	44 ARK Genomic Revolution ETF ARKG $2.01B	–	–	–	–
45	45 Artiva Biotherapeutics ARTV $293M	–	–	–	–
46	ATNX 46 DELISTED Athenex, Inc. Common Stock ATNX	–	–	–	–
47	47 Atara Biotherapeutics ATRA $94.3M	–	–	–	–
48	48 Autolus Therapeutics AUTL $455M	–	–	–	–
49	49 BridgeBio Pharma BBIO $13B	–	–	–	–
50	50 BioCardia BCDA $13.2M	–	–	–	–